Drugs / autologous activated platelet-rich plasma
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04715360 | Dec 2020 → Nov 2021 | COVID-19, acute respiratory distress syndrome | Hayandra Peduli Foundation | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous activated platelet-rich plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04715360 ↗ |
| Known as | aaPRP | “In this study, we aimed to evaluate the potential of autologous activated platelet-rich plasma (aaPRP) and the outcomes for treating severe Coronavirus Disease-2019 (COVID-19)...” NCT04715360 ↗ |
| Known as | PRP | “activated platelet-rich plasma (PRP) produces anti-inflammatory effects in inflammatory condition that is beneficial for tissue regeneration.” NCT04715360 ↗ |
| Action | Inhibit | “PRP decreases IL-1β, IL-6, IL-8, and TNFα inflammatory genes expression while also reduces IL-1β and TNFα inflammatory cytokines production.” NCT04715360 ↗ |
| Route | Other | “autologous activated platelet-rich plasma transfusion” NCT04715360 ↗ |
| Target | TNF | “PRP decreases IL-1β, IL-6, IL-8, and TNFα inflammatory genes expression while also reduces IL-1β and TNFα inflammatory cytokines production.” NCT04715360 ↗ |